Source link : https://www.newshealth.biz/health-news/isatuximab-quadruplet-approval-could-change-mm-landscape/
RIO DE JANEIRO — Adding isatuximab, or Isa (Sarclisa, Sanofi-Aventis), to bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma reduced the risk for disease progression or death by more than 40% vs VRd alone in the randomized, global, open-label, phase 3 IMROZ trial. The findings, presented on […]
Author : News Health
Publish date : 2024-10-04 11:22:54
Copyright for syndicated content belongs to the linked Source.